Royalty Pharma RPRX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.61B-3.3% | $2.49B-10.1% | $2.41B-14.1% | $2.41B-9.8% | $2.7B+3.1% | ||
| -$2.6B-24.4% | -$1.61B+39.7% | -$1.27B+59.9% | -$1.51B+38.0% | -$2.09B-30.4% | ||
| $568.7M-39.4% | $1.23B+434% | $1.2B+479% | $1.15B+359% | $938.43M— | ||
| —— | —— | —— | —— | —— | ||
| -$501.33M— | -$310.33M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Royalty Pharma generate?
- Royalty Pharma (RPRX) generated $2.6B in operating cash flow over the trailing twelve months.
- Where does Royalty Pharma's cash flow data come from?
- Every line is extracted from Royalty Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
